recombinant murine interleukin-12

Recombinant murine interleukin-12 (rmIL-12) is a heterodimeric cytokine composed of p35 and p40 subunits, produced through recombinant DNA technology. It serves as a potent immunomodulatory agent that binds to the IL-12 receptor on T cells, natural killer (NK) cells, and dendritic cells, subsequently activating the JAK/STAT signaling pathway. Its primary biological activity involves promoting T helper type 1 (Th1) immune responses, inducing the secretion of interferon-gamma (IFN-γ), and enhancing the cytotoxic activity of CD8+ T cells and NK cells. In preclinical research, rmIL-12 has demonstrated significant anti-tumor and anti-metastatic effects across various models, including acute myeloid leukemia (AML), melanoma, and infectious diseases like Leishmania major. While systemic administration has shown efficacy in delaying tumor growth, its clinical utility is often limited by dose-dependent toxicity, leading to the investigation of local delivery methods or gene-modified tumor cell vaccines (e.g., IL12-AML) to achieve therapeutic outcomes without adverse systemic effects.

Other names

recombinant mouse interleukin-12murine IL-12